← FDA DRUG APPROVALS

FDA ANDA · ANDA040023

ADRUCIL

Sponsor: TEVA PARENTERAL

APPLICATION
ANDA040023
TYPE
ANDA
ORIGINAL APPROVAL
1991-10-18
LATEST ACTION
1999-09-13
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

ADRUCILDiscontinued
FLUOROURACIL 50MG/ML · INJECTABLE · INJECTION

Approval history

1999-09-13Labeling · Supplement 6AP
1997-09-12Labeling · Supplement 4AP
1992-11-04Manufacturing (CMC) · Supplement 3AP
1992-07-10Manufacturing (CMC) · Supplement 1AP
1991-10-18OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →